Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...